Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)
ANNALS OF ONCOLOGY. Bd. 29. 2018 S. 208-208
Erscheinungsjahr: 2018
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Zhu, A. X. (Autor)
Finn, R. S. (Autor)
Galle, P. R. (Autor)
Llovet, J. M. (Autor)
Blanc, J. F. (Autor)
Okusaka, T. (Autor)
Chau, I. (Autor)
Cella, D. (Autor)
Girvan, A. (Autor)
Gable, J. (Autor)
Bowman, L. (Autor)
Hsu, Y. (Autor)
Abada, P. B. (Autor)
Kudo, M. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
